Exelixis, Inc.

NasdaqGS:EXEL 주식 보고서

시가총액: US$10.2b

Exelixis 관리

관리 기준 확인 4/4

Exelixis CEO는 Mike Morrissey, Jul2010 에 임명되었습니다 의 임기는 14.33 년입니다. 총 연간 보상은 $ 16.42M, 7.3% 로 구성됩니다. 7.3% 급여 및 92.7% 보너스(회사 주식 및 옵션 포함). 는 $ 57.14M 가치에 해당하는 회사 주식의 0.56% 직접 소유합니다. 57.14M. 경영진과 이사회의 평균 재임 기간은 각각 8.5 년과 7.4 년입니다.

주요 정보

Mike Morrissey

최고 경영자

US$16.4m

총 보상

CEO 급여 비율7.3%
CEO 임기14.3yrs
CEO 소유권0.6%
경영진 평균 재임 기간8.5yrs
이사회 평균 재임 기간7.4yrs

최근 관리 업데이트

Recent updates

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Oct 31

Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Oct 31
Exelixis, Inc.'s (NASDAQ:EXEL) Shares Leap 25% Yet They're Still Not Telling The Full Story

Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Oct 26
Here's Why We Think Exelixis (NASDAQ:EXEL) Is Well Worth Watching

Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Sep 02
Getting In Cheap On Exelixis, Inc. (NASDAQ:EXEL) Might Be Difficult

Exelixis Comes Up Aces

Aug 08

If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

Jun 14
If EPS Growth Is Important To You, Exelixis (NASDAQ:EXEL) Presents An Opportunity

It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

May 24
It's Unlikely That Exelixis, Inc.'s (NASDAQ:EXEL) CEO Will See A Huge Pay Rise This Year

Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

May 07
Exelixis' (NASDAQ:EXEL) Strong Earnings Are Of Good Quality

Exelixis: With Patent Litigation Decision Due Soon, There Are Options

May 02

Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Apr 22
Exelixis, Inc.'s (NASDAQ:EXEL) Earnings Haven't Escaped The Attention Of Investors

Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024

Mar 28

We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Feb 26
We Ran A Stock Scan For Earnings Growth And Exelixis (NASDAQ:EXEL) Passed With Ease

Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles

Jan 17

Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

Dec 27
Exelixis, Inc.'s (NASDAQ:EXEL) Revenues Are Not Doing Enough For Some Investors

An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

May 30
An Intrinsic Calculation For Exelixis, Inc. (NASDAQ:EXEL) Suggests It's 49% Undervalued

CEO 보상 분석

Mike Morrissey 의 보수는 Exelixis 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

US$467m

Jun 30 2024n/an/a

US$350m

Mar 31 2024n/an/a

US$205m

Dec 31 2023n/an/a

US$208m

Sep 30 2023n/an/a

US$92m

Jun 30 2023n/an/a

US$164m

Mar 31 2023n/an/a

US$154m

Dec 31 2022US$17mUS$1m

US$182m

Sep 30 2022n/an/a

US$308m

Jun 30 2022n/an/a

US$273m

Mar 31 2022n/an/a

US$298m

Dec 31 2021US$8mUS$1m

US$231m

Sep 30 2021n/an/a

US$164m

Jun 30 2021n/an/a

US$94m

Mar 31 2021n/an/a

US$65m

Dec 31 2020n/an/a

US$112m

Sep 30 2020n/an/a

US$152m

Jun 30 2020n/an/a

US$282m

Mar 31 2020n/an/a

US$294m

Dec 31 2019n/an/a

US$321m

Sep 30 2019n/an/a

US$612m

Jun 30 2019n/an/a

US$642m

Mar 31 2019n/an/a

US$650m

Dec 31 2018n/an/a

US$690m

Sep 30 2018n/an/a

US$368m

Jun 30 2018n/an/a

US$323m

Mar 31 2018n/an/a

US$253m

Dec 31 2017n/an/a

US$154m

보상 대 시장: Mike 의 총 보상 ($USD 16.42M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 12.66M ).

보상과 수익: Mike 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Mike Morrissey (63 yo)

14.3yrs

테뉴어

US$16,423,307

보상

Dr. Michael M. Morrissey, Ph.D. also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24,...

리더십 팀

이름위치테뉴어보상소유권
Stelios Papadopoulos
Co-Founder & Chair of the Board29.9yrsUS$519.97k0.43%
$ 44.2m
Michael Morrissey
CEO, President & Director14.3yrsUS$16.42m0.56%
$ 57.1m
Christopher Senner
Executive VP & CFO9.3yrsUS$4.95m0.16%
$ 16.6m
Dana Aftab
Executive VP of Discovery and Translational Research & Chief Scientific Officer1.9yrsUS$5.65m0.080%
$ 8.1m
Jeffrey Hessekiel
Executive VP & General Counsel10.8yrsUS$4.56m0.11%
$ 11.0m
Amy Peterson
Executive VP1.3yrsUS$7.38m0.10%
$ 10.5m
Susan Hubbard
Executive Vice President of Public Affairs & Investor Relations7.9yrs데이터 없음데이터 없음
Tony Redmond
Senior Vice President of Human Resourcesless than a year데이터 없음데이터 없음
Anne Champsaur
Senior Vice President of Drug Safety9.6yrs데이터 없음데이터 없음
William Berg
Senior Vice President of Medical Affairs9.2yrs데이터 없음데이터 없음
Patrick Haley
Executive Vice President of Commercial7.9yrsUS$4.65m0.039%
$ 4.0m
Stefan Krauss
VP & Head of Business Developmentno data데이터 없음데이터 없음

8.5yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: EXEL 의 관리팀은 노련하고 경험 (평균 재직 기간 8.5 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Stelios Papadopoulos
Co-Founder & Chair of the Board29.9yrsUS$519.97k0.43%
$ 44.2m
Michael Morrissey
CEO, President & Director14.3yrsUS$16.42m0.56%
$ 57.1m
Jack Wyszomierski
Independent Director20.8yrsUS$490.97k0.12%
$ 11.8m
George Poste
Independent Director20.3yrsUS$482.22k0.053%
$ 5.3m
Charles Sawyers
Member of the Scientific Advisory Boardno data데이터 없음데이터 없음
Ronald Evans
Member of the Scientific Advisory Boardno data데이터 없음데이터 없음
Sue Eckhardt
Independent Directorless than a year데이터 없음0%
$ 0
Mary Beckerle
Independent Directorless than a year데이터 없음0%
$ 0
Julie Smith
Independent Director8.2yrsUS$490.92k0.00027%
$ 27.5k
Maria Freire
Independent Director6.6yrsUS$488.72k0.025%
$ 2.6m
Robert Oliver
Independent Director1.5yrsUS$717.44k0.0016%
$ 161.7k
Tomas Heyman
Independent Director1.5yrsUS$716.19k0.0016%
$ 161.7k

7.4yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: EXEL 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.